Maxim Group Thinks MYnd Analytics Inc’s Stock is Going to Recover


Maxim Group analyst Anthony Vendetti maintained a Buy rating on MYnd Analytics Inc (MYND) today and set a price target of $5. The company’s shares closed yesterday at $1.11, close to its 52-week low of $0.62.

Vendetti noted:

“Yesterday, MYND announced that it entered into a merger agreement with Emmaus Life Sciences (private), a leader in sickle cell disease treatment.”

According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 3.1% and a 49.6% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Restoration Robotics Inc, Xtant Medical Holdings, and Ra Medical Systems Inc.

MYnd Analytics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.08 and a one-year low of $0.62. Currently, MYnd Analytics Inc has an average volume of 249.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MYnd Analytics, Inc. operates as a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts